Literature DB >> 1517959

Fatal systemic candidiasis of gastrointestinal origin: an experimental model in mice compromised by anti-cancer treatment.

H Sandovsky-Losica1, L Barr-Nea, E Segal.   

Abstract

An experimental model of fatal systemic candidiasis originating from the gastrointestinal (GI) tract of compromised mice is presented. ICR female mice were compromised by a single anti-cancer treatment: irradiation (4 or 6 Greys i.e. 400-600 rads), methotrexate (MTX) (3 mg per mouse, intraperitoneally) or 5-fluorouracil (5FU) (200 mg kg-1, intravenously). Three days later, compromised and non-treated control mice were exposed to Candida albicans administered orally. Morbidity and mortality due to candidiasis were monitored for 30 days post-candidal inoculation. Increased and longer GI colonization was noted among the MTX and 5FU treated mice, or 6 Greys irradiated mice (up to 92.3% for over 30 days in anti-cancer treated mice). The stomach was found to be the major part of the GI tract involved in fungal colonization. A significant number (53.8-83.3%) of the anti-cancer treated mice developed systemic candidiasis originating from the GI tract, which was fatal in 30-80% of the infected animals. In systemically infected animals, candidal antigen was demonstrated in the serum, and fungal abscesses containing C. albicans were observed in the liver, kidneys and spleen. C. albicans was isolated from the infected organs. The severity of the infection, as reflected by the number of fungi in visceral organs, and by mortality during the 30 days post-candidal inoculation, indicated differences in the course and nature of the infection among the three treatment groups (i.e. MTX, 5FU, 6 Greys).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517959     DOI: 10.1080/02681219280000281

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN: 0268-1218


  6 in total

1.  Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs.

Authors:  Karl V Clemons; Gloria M Gonzalez; Gaurav Singh; Jackie Imai; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

2.  Hosting infection: experimental models to assay Candida virulence.

Authors:  Donna M Maccallum
Journal:  Int J Microbiol       Date:  2011-12-22

Review 3.  Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Authors:  Patrick Van Dijck; Jelmer Sjollema; Bruno P Cammue; Katrien Lagrou; Judith Berman; Christophe d'Enfert; David R Andes; Maiken C Arendrup; Axel A Brakhage; Richard Calderone; Emilia Cantón; Tom Coenye; Paul Cos; Leah E Cowen; Mira Edgerton; Ana Espinel-Ingroff; Scott G Filler; Mahmoud Ghannoum; Neil A R Gow; Hubertus Haas; Mary Ann Jabra-Rizk; Elizabeth M Johnson; Shawn R Lockhart; Jose L Lopez-Ribot; Johan Maertens; Carol A Munro; Jeniel E Nett; Clarissa J Nobile; Michael A Pfaller; Gordon Ramage; Dominique Sanglard; Maurizio Sanguinetti; Isabel Spriet; Paul E Verweij; Adilia Warris; Joost Wauters; Michael R Yeaman; Sebastian A J Zaat; Karin Thevissen
Journal:  Microb Cell       Date:  2018-06-14

4.  Candida albicans induces mucosal bacterial dysbiosis that promotes invasive infection.

Authors:  Martinna Bertolini; Amit Ranjan; Angela Thompson; Patricia I Diaz; Takanori Sobue; Kendra Maas; Anna Dongari-Bagtzoglou
Journal:  PLoS Pathog       Date:  2019-04-22       Impact factor: 7.464

Review 5.  Experimental in Vivo Models of Candidiasis.

Authors:  Esther Segal; Michael Frenkel
Journal:  J Fungi (Basel)       Date:  2018-02-06

Review 6.  Animal models: an important tool in mycology.

Authors:  Javier Capilla; Karl V Clemons; David A Stevens
Journal:  Med Mycol       Date:  2007-12       Impact factor: 4.076

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.